Home
Live Updates
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea : comparemela.com
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
PIVLAZ™, a new drug for prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH), approved in South KoreaPIVLAZ...
Related Keywords
United Kingdom ,
Cambridge ,
Cambridgeshire ,
London ,
City Of ,
China ,
Seoul ,
Soult Ukpyolsi ,
South Korea ,
Tokyo ,
Japan ,
Bucheon ,
Kyonggi Do ,
Japanese ,
J Clin Neurosci ,
Erica Hollingsworth ,
Sosei Heptares ,
Satoshi Tanaka ,
Frazer Hall ,
Maya Bennison ,
Kentaro Tahara ,
Shinichiro Nishishita ,
Sosei Group Corporation ,
Tokyo Stock Exchange ,
Ministry Of Food ,
Youtube ,
Linkedin ,
Medistrava Consulting For International Media ,
Korean Society Of Cerebrovascular Surgeons Professor ,
Idorsia Pharmaceuticals Korea ,
Idorsia Pharmaceuticals Korea Co Ltd ,
Idorsia Pharmaceuticals Japan ,
Sosei Group ,
Sosei Group Corporation Heptares ,
Cerebral Vasospasm ,
Aneurysmal Subarachnoid Hemorrhage ,
Drug Safety ,
Japanese Phase ,
Marketing Authorization ,
Park Ik Seong ,
Korean Society ,
Cerebrovascular Surgeons ,
Executive Officer ,
Executive Vice President ,
Idorsia Pharmaceuticals Ltd ,
Pharmacol Exp ,
Lancet Neurology ,
Pharmaceuticals Korea ,
Corporate Strategy ,
International Media ,
comparemela.com © 2020. All Rights Reserved.